Market Pulse
AI
4 events
AI trade turns more selective as hyperscalers push custom silicon, IPO pipeline firms, fintech buys routing, and China cloud capex spikes.
Latest Development
Google can buy up to 58.97M Marvell shares at $206.58, with purchases tied to program purchase targets through Marvell fiscal 2033 for TPU-ecosystem inference, storage, and NIC products.
OpenAI’s CFO told employees an IPO is targeted for 2027 and could come earlier; she said a confidential SEC filing was made in June and cited QTD run-rate growth and 20M weekly active users.
Stripe announced plans to acquire model-routing startup OpenRouter; the NYT pegged the price near $7.5B versus a ~$1.3B valuation in a recent round, expanding into token-cost optimization and routing economics.
Alibaba reported June-quarter net income down 75% y/y as capex rose 75% to 67.7B yuan; revenue grew 9% to 268.95B yuan in line, while cloud revenue jumped 45% to 48.4B yuan.
Market reaction
MRVL rose about 10% on the expanded Google partnership while AVGO fell about 5% the same day; BABA was volatile premarket, down ~4% initially and later around -1.6%.
Our view
AI exposure remains a capex-led growth theme but stock selection should dominate as custom-silicon strategies and pricing/cost inflation reshuffle winners across semis, platforms, and infrastructure. Next check is whether program milestones and purchase targets translate into sustained orders, while cloud growth offsets profit drag from accelerating spend.
What could change our view
Google TPU program targets slip, reducing MRVL share purchases and associated volumes.
Capex intensity rises faster than monetization, extending profit pressure despite cloud growth.
Tickers: $MRVL, $QQQ, $PYPL, $BABA
Retail
3 events
Retail split widens as Walmart and Target lift full-year outlooks on tariff refunds while Lowe’s trims guidance amid softer DIY demand.
Latest Development
Walmart posted fiscal Q2 revenue of $187.94B (+5.9% y/y) with global e-commerce +23%, raised FY net sales growth to 4%–5%, and plans to use about $2.9B of tariff refunds to lower prices in Q3.
Target reported fiscal Q2 sales +5.3% y/y and comps +3.8%, said tariff refunds boosted earnings by $752M ($1.65/sh), and raised FY sales growth to ~5% while lifting EPS guidance to $9.90–$10.90 including refunds.
Lowe’s shifted FY guidance to the low end as DIY project demand softened, setting sales at $92B with comps flat and adjusted EPS at $12.25, citing project spending pressure and heightened July competitive intensity.
Our view
Favor large-scale value retailers versus home-improvement exposure, as tariff-refund tailwinds support pricing investment and traffic while DIY spending remains pressured. Watch Q3 price actions funded by refunds and any incremental fuel-cost drag on consumer sensitivity, plus signs of housing-linked demand thaw affecting Lowe’s/peers.
What could change our view
Tariff-refund benefits fade and price investments erode gross profit rates.
Housing recovery accelerates, lifting DIY demand and reversing Lowe’s guidance pressure.
Tickers: $WMT, $TGT, $LOW
Macro & Policy Digest
Policy-regulation headlines from Trump spark broad crypto risk-on lifting BTC/ETH and IBIT volumes while raising questions for US exchange incumbents.
Latest Development
Trump urged Congress to pass the crypto “Clarity Act”; bitcoin rose ~5.2% to ~$71,880 and ether ~9% to ~$2,288 as long-end yields fell after Treasury boosted 20- and 30-year buybacks, with IBIT volume >4.5x average.
Trump said the CFTC is working to bring Hyperliquid “onshore” compliantly; HYPE token gained ~25% in 24 hours and HYPE-treasury vehicle PURR rose ~30% intraday as Coinbase climbed ~10% and Strategy ~13% while CBOE and CME slid.
Market reaction
Crypto ripped on the policy impulse: bitcoin +~5.2% to ~$71,880 and ether +>9% to ~$2,288, with IBIT volume reported >4.5x its 30-day average and BTC implied vol (BVIV) back above 40. Spillovers were sharp—HYPE +~25%, PURR +~30% with call-heavy options flow—while exchange incumbents sold off (CBOE -~3.5%, CME -~1.7%) and crypto-beta equities bounced (COIN +~10%, MSTR +~13%).
Our view
Headline-driven regulatory-clarity optimism keeps near-term upside bias for BTC proxies like IBIT, but with higher volatility and intra-sector dispersion. The next swing factor is whether the “Clarity Act” advances materially and whether CFTC steps on Hyperliquid translate into actionable rulemaking or registration progress.
What could change our view
Clarity Act stalls or faces adverse amendments reversing regulatory-clarity optimism.
CFTC/Hyperliquid ‘onshore’ effort triggers pushback tightening rather than expanding access.
Tickers: $IBIT
Korea peninsula risk premium in focus after shortened U.S.–South Korea drills and Trump’s specific North Korea nuclear count with potential summit signaling.
Latest Development
President Trump ordered a substantial reduction in joint U.S.–South Korea military exercises, shortening Ulchi Freedom Shield to end Friday instead of running through Aug. 27; officials said essential readiness goals would be preserved.
Trump said North Korea has “57 nuclear weapons” and indicated he expects to meet Kim Jong Un later this year, while Kim Yo Jong reportedly dismissed the drill reduction as insufficient.
Our view
Elevated headline-driven volatility rather than a durable de-escalation, with defense and safe-haven sensitivity skewed to any further signaling from Washington or Pyongyang. Next to watch is Pentagon follow-on guidance on future exercises and any confirmation, timing, or cancellation around a Trump–Kim meeting.
What could change our view
A confirmed Trump–Kim meeting with credible de-escalation steps reduces risk premium.
North Korean response actions or sharper rhetoric reprice tail-risk quickly across risk and havens.
Tickers: $ITA
Treasury plans to at least double 10–30Y buybacks over two months, easing long-end yields and nudging cross-asset risk sentiment.
Latest Development
Treasury said it will at least double 10–30Y buyback operations for roughly two months, raising the max per operation to at least $4B from $2B.
Market reaction
After the announcement, the 30Y yield fell about 10 bps to ~5.18–5.19% and the 10Y fell ~6 bps to ~4.64%; equities rose ~0.2%, the USD weakened ~0.8%, and gold and bitcoin rallied, with yields later ticking back up modestly.
Our view
The stepped-up long-end buybacks help cap term premium and support duration (TLT) in the near term, but the effect should fade without sustained demand improvement. Monitor the published operation schedule, 20Y/30Y auction tails, and 10s30s curve response for stabilization.
What could change our view
Operation sizes or cadence disappoint versus guidance, term premium re-widens.
Weak 20Y/30Y auctions steepen 10s30s and negate buyback support.
Tickers: $TLT
U.S.–Canada trade deal edges closer as Trump pauses threatened 50% tariffs on about $20B of Canadian imports until early Saturday.
Latest Development
Trump said a tentative U.S.–Canada deal is pending final documents and delayed threatened 50% tariffs on about $20B of Canadian imports for three days, now slated for 12:01 a.m. Saturday.
Our view
The three-day pause reduces immediate trade-friction tail risk, but pricing should stay rangebound until documents are finalized and implementation is clarified. Monitor whether the tariff start time is extended again versus a signed agreement that specifies agriculture access and any steel/aluminum tariff adjustments.
What could change our view
Documents fail and 50% tariffs begin at 12:01 a.m. Saturday.
Canada holds firm on supply management, derailing claimed agricultural tariff elimination.
Tickers: $EWC
U.S. escalates “Economic D-Day” sanctions on Iran as Hormuz transits stay below norms, keeping a modest oil risk premium.
Latest Development
Trump announced a major sanctions escalation targeting Iran and third-country “lifelines,” while Lloyd’s List data showed Hormuz transits still below pre-war norms at 73 vs 91 prior week.
Market reaction
Brent rose 0.5% to $92.09 and WTI gained 0.3% to $86.07; S&P 500 futures reportedly pared gains to near-flat after the headline.
Our view
Range-bound crude with a persistent geopolitical premium as sanctions rhetoric meets already-dislocated shipping flows. Key monitor is any shift from economic measures to military escalation, or a further drop in Hormuz transits that tightens physical supply risk.
What could change our view
Iran military escalation that materially worsens Hormuz shipping disruption.
Rapid diplomatic de-escalation that restores transit flows toward pre-war norms.
Tickers: $CL=F
Somali piracy returns near the Gulf of Aden, compounding Red Sea security stress and raising the odds of higher war-risk premiums and longer voyages.
Latest Development
CNBC reported the cargo vessel Lutuf was seized Aug. 17 by eight armed men about four nautical miles off Somalia; a Tanzanian-flagged oil/chemical tanker was also taken earlier and moved toward Puntland.
Our view
Treat this as a freight-and-differentials shock more than an outright supply-loss driver, with the near-term impulse toward higher insurance costs and tighter effective tanker capacity. Monitor for signs of capability migration beyond ransom hijackings, which would push broader route avoidance.
What could change our view
Evidence of drones or missiles shifting the threat from ransom to kinetic attacks.
Sustained route avoidance materially tightening tanker capacity and widening crude/product differentials.
Tickers: $CL=F
Company Events
Moderna and Merck’s personalized mRNA cancer vaccine plus Keytruda cleared a Phase 3 melanoma endpoint, opening a filing path and repricing oncology optionality.
Latest Development
Moderna and Merck said intismeran autogene plus Keytruda beat Keytruda alone on the Phase 3 primary endpoint in >1,100 resected higher-risk/advanced melanoma patients, with no new safety signals; full data to be presented at an upcoming meeting.
Market reaction
Moderna surged about 177% to $174.38 and Merck rose about 12% on the Phase 3 win, reflecting a sharp reassessment of Moderna’s oncology platform and nearer-term financing optionality.
Our view
We expect follow-through strength in MRNA with MRK supported, as investors price a credible regulatory path and broadened oncology platform value. The next decisive catalyst is the full data disclosure (including hazard ratios) at the upcoming medical meeting and subsequent filing clarity.
What could change our view
Full dataset reveals weaker-than-expected hazard ratios or limited clinical effect size.
Regulatory setbacks or safety/tolerability concerns emerge during review or additional analyses.
Tickers: $MRNA
Bally’s going-concern warning puts refinancing and liquidity execution in focus as the company pursues asset monetization, equity sale and incremental debt.
Latest Development
Bally’s SEC-filed Q2 report raised substantial doubt about continuing as a going concern over the next 12 months, outlining asset sales, an equity raise and additional debt, plus a non-binding July loan term sheet.
Market reaction
BALY shares fell more than 35.9% over the past five trading days after the warning and were down more than 46.8% year-to-date (per the article).
Our view
Treat BALY as a stressed-credit situation where the equity is effectively trading the probability and terms of near-term financing. Next key monitor is conversion of the July non-binding term sheet into a binding agreement alongside any announced asset monetization or equity issuance terms.
What could change our view
Failure to secure binding financing or asset monetization on acceptable terms.
Refinancing outcomes drive large dilution or punitive covenants that impair flexibility.
Tickers: $BALY
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.